Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,018.39 -17.30 (-0.34%) Dow
37,903.29 +87.37 (+0.23%) Nasdaq
15,605.48 -52.34 (-0.33%) Bitcoin USD
57,748.63 +632.94 (+1.11%) CMC Crypto 200
1,266.21 -4.53 (-0.36%)
Eli Lilly and Company (LLY)
Pre-market:
| Previous close | 781.10 |
| Open | 774.76 |
| Bid | 0.00 x 1200 |
| Ask | 775.50 x 1100 |
| Day's range | 768.25 - 782.60 |
| 52-week range | 419.80 - 800.78 |
| Volume | |
| Avg. volume | 3,116,267 |
| Market cap | 738.227B |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 114.90 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 5.20 (0.67%) |
| Ex-dividend date | 14 Feb 2024 |
| 1y target est | N/A |
- Yahoo Finance
3 stocks with the biggest gains took April's biggest losses
The stock market's very rough April saw some of the biggest gainers of the first three months take some of the biggest dings to their market caps. And at the same time, some of the sectors that struggled in Q1 saw a similar reversal of fortune in April.
- Reuters
UPDATE 5-Novo Nordisk raises outlook fuelled by obesity drug demand
Novo Nordisk raised its 2024 outlook on Thursday and delivered better-than-expected first-quarter profits as the Danish drugmaker races to boost output of its Wegovy weight-loss drug and fend off competition from rival Eli Lilly. Novo is currently the most valuable company in Europe by market capitalisation, worth some 540.4 billion euro ($576.44 billion) before earnings on Thursday, on the back of Wegovy's popularity. Sales growth in the U.S. was positively impacted by a one-off sales adjustment, the company said.
- Reuters
Novo Nordisk raises outlook fuelled by obesity drug demand
LONDON (Reuters) -Novo Nordisk raised its 2024 outlook on Thursday and delivered better-than-expected first-quarter profits as the Danish drugmaker races to boost output of its Wegovy weight-loss drug and fend off competition from rival Eli Lilly. Novo is currently the most valuable company in Europe by market capitalisation, worth some 540.4 billion euro ($576.44 billion) before earnings on Thursday, on the back of Wegovy's popularity. Sales growth in the U.S. was positively impacted by a one-off sales adjustment, the company said.
